Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
AMINOSYN 3.5% M IN PLASTIC CONTAINER vs TRAVASOL 5.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a mixture of essential and non-essential amino acids used for parenteral nutrition. It provides substrates for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth.
Travasol 5.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting metabolic functions in parenteral nutrition.
Intravenous infusion: 500 mL to 1 L of 3.5% amino acid solution per day for adults; rate not to exceed 0.1 g amino acids/kg/hr.
500 mL of 5.5% amino acid solution intravenously over 2-4 hours daily, titrated to nitrogen balance and metabolic tolerance.
None Documented
None Documented
Variable (minutes to hours) due to rapid metabolic utilization; terminal half-life in plasma is <10 minutes for most amino acids.
Not applicable as individual amino acids have variable half-lives (minutes to hours). TRAVASOL is a mixture; the clinical context is continuous infusion to maintain plasma levels.
Renal: >90% as amino acids and metabolites; negligible biliary/fecal elimination.
Amino acids in TRAVASOL 5.5% are metabolized and nitrogen waste is excreted primarily via renal elimination (as urea, >90% of nitrogen). Fecal elimination is negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution